Science Explorer Back to mapMap
Discussion
Company · Stockholm · Sweden

Glucox Biotech (Sweden)

glucoxbiotech.comROR OpenAlex
Research works
6
▼ 3% vs 2018-21
Citations
157
27.2 per fractional work
Top-10% rate
20.2%
all institutions 10.0%
Open access
74%
world 40%
International
49%
world 18%
Glucox Biotech (Sweden)

Not ranked overall: Glucox Biotech (Sweden) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Glucox Biotech (Sweden) work in?

In all years, 53% of research at Glucox Biotech (Sweden) is in Life Sciences, 38% in Health Sciences. Its largest fields are Medicine (37%), Biochemistry, Genetics and Molecular Biology (32%), Immunology and Microbiology (16%). It does 1.6× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 52.7% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 32.0% of its workMolecular Biology: 1 fractional works · 17.0% of its workGenetics: 0 fractional works · 7.7% of its workCancer Research: 0 fractional works · 5.7% of its workClinical Biochemistry: 0 fractional works · 1.4% of its workSmaller subfields together: 0 fractional works · 0.2% of its workImmunology and Microbiology: 1 fractional works · 16.3% of its workImmunology: 1 fractional works · 16.3% of its workNeuroscience: 0 fractional works · 3.0% of its workNeurology: 0 fractional works · 3.0% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 1.4% of its workToxicology: 0 fractional works · 1.4% of its workHealth Sciences: 2 fractional works · 38.1% of its workMedicine: 2 fractional works · 36.7% of its workPhysiology: 1 fractional works · 12.0% of its workSurgery: 1 fractional works · 11.7% of its workOphthalmology: 0 fractional works · 4.3% of its workPathology and Forensic Medicine: 0 fractional works · 3.3% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.9% of its workNephrology: 0 fractional works · 1.9% of its workRehabilitation: 0 fractional works · 1.4% of its workVeterinary: 0 fractional works · 1.4% of its workSmall Animals: 0 fractional works · 1.4% of its workPhysical Sciences: 1 fractional works · 9.2% of its workEnvironmental Science: 0 fractional works · 5.7% of its workHealth, Toxicology and Mutagenesis: 0 fractional works · 5.7% of its workEngineering: 0 fractional works · 2.1% of its workBiomedical Engineering: 0 fractional works · 2.1% of its workComputer Science: 0 fractional works · 1.4% of its workComputational Theory and Mathematics: 0 fractional works · 1.4% of its workALL ITS WORKGlucox Biotech(Sweden)6fractional works, all years
Life Sciences53%Physical Sciences9%Health Sciences38%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 3 domains and 9 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology232.0%
    2. Immunology and Microbiology116.3%
    3. Neuroscience03.0%
    4. Pharmacology, Toxicology and Pharmaceutics01.4%
    1. Medicine236.7%
    2. Veterinary01.4%
    1. Environmental Science05.7%
    2. Engineering02.1%
    3. Computer Science01.4%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Who are the top researchers at Glucox Biotech (Sweden)?

Ranked on the quality score, Per Wikström lead among researchers whose main affiliation is Glucox Biotech (Sweden).

  1. 1 Per Wikström Sweden · #1,186,276 worldwide 1.1k citations · 29 works
All ranked researchers at Glucox Biotech (Sweden)

What are the most cited papers from Glucox Biotech (Sweden)?

The most cited paper from Glucox Biotech (Sweden) is "The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice" (Enayat Anvari, Pernilla Wikström, Erik Walum et al., 2015), with 101 citations. Next come "The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro" (74) and "Shikonin Increases Glucose Uptake in Skeletal Muscle Cells and Improves Plasma Glucose Levels in Diabetic Goto-Kakizaki Rats" (48).

Most cited papers
#PaperReleasedCitations
1 The novel NADPH oxidase 4 inhibitor GLX351322 counteracts glucose intolerance in high-fat diet-treated C57BL/6 mice Enayat Anvari, Pernilla Wikström, Erik Walum et al. · Free Radical Research Open access 29 Jun 2015 101
2 The novel NADPH oxidase 4 selective inhibitor GLX7013114 counteracts human islet cell death in vitro Xuan Wang, Andris Elksnis, Per Wikström et al. · PLoS ONE Open access 28 Sep 2018 74
3 Shikonin Increases Glucose Uptake in Skeletal Muscle Cells and Improves Plasma Glucose Levels in Diabetic Goto-Kakizaki Rats Anette I. Öberg, Kamal Yassin, Robert I. Csikasz et al. · PLoS ONE Open access 26 Jul 2011 48
4 Diphenylene iodonium stimulates glucose uptake in skeletal muscle cells through mitochondrial complex I inhibition and activation of AMP-activated protein kinase Dana S. Hutchinson, Robert I. Csikasz, Daniel L. Yamamoto et al. · Cellular Signalling 22 Feb 2007 45
5 Topically Administered NOX4 Inhibitor, GLX7013114, Is Efficacious in Treating the Early Pathological Events of Diabetic Retinopathy Stavroula Dionysopoulou, Per Wikström, Claudio Bucolo et al. · Diabetes Open access 23 Feb 2023 43
All 15 most cited papers, with filters and sorting

Which research topics does Glucox Biotech (Sweden) publish most on?

By volume in 2022-now: Retinal Diseases and Treatments, Neutrophil, Myeloperoxidase and Oxidative Mechanisms, Retinal Development and Disorders and Pancreatic function and diabetes.

Retinal Diseases and Treatments: 0 fractional worksNeutrophil, Myeloperoxidase and Oxidative Mechanisms: 0 fractional worksRetinal Development and …0Retinal Development and Disorders: 0 fractional worksPancreatic function and …0Pancreatic function and diabetes: 0 fractional worksMetabolism, Diabetes, an…0Metabolism, Diabetes, and Cancer: 0 fractional worksDiabetes and associated …0Diabetes and associated disorders: 0 fractional worksAdvanced Glycation End Products research: 0 fractional worksAcute Kidney Injury Research: 0 fractional worksNitric Oxide and Endothelin Effects: 0 fractional worksCardiac Ischemia and Reperfusion: 0 fractional works
OphthalmologyImmunologyMolecular BiologySurgery5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Retinal Diseases and Treatments Ophthalmology 0 works
  2. 2 Neutrophil, Myeloperoxidase and Oxidative Mechanisms Immunology 0 works
  3. 3 Retinal Development and Disorders Molecular Biology 0 works
  4. 4 Pancreatic function and diabetes Surgery 0 works
  5. 5 Metabolism, Diabetes, and Cancer Molecular Biology 0 works
  6. 6 Diabetes and associated disorders Genetics 0 works
  7. 7 Advanced Glycation End Products research Clinical Biochemistry 0 works
  8. 8 Acute Kidney Injury Research Nephrology 0 works
  9. 9 Nitric Oxide and Endothelin Effects Physiology 0 works
  10. 10 Cardiac Ischemia and Reperfusion Pathology and Forensic Medicine 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available73.7%not open26.3%

World: 40% of research is openly available.

with international co-authors49.4%domestic only50.6%

World: 18% is written across borders.

How has Glucox Biotech (Sweden)'s research output changed?

Output in 2022-2025 was 3% lower than in 2018-2021.

201020152020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Glucox Biotech (Sweden) as a percentage of every work published that year, 0.000014% in 2023.

0.000010%0.000020%0.000030%Glucox Biotech (Sweden)0.000015% in 202420102020

Fractional works of Glucox Biotech (Sweden) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Stockholm

All research institutions in Stockholm

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Glucox Biotech (Sweden). Posts are plain text and can be reported.